Chinook's Kidney Disease Candidate Continues To Show Rapid, Sustained Reductions In Biomarkers

  • Chinook Therapeutics Inc KDNY announced updated interim results from the Phase 1/2 study of BION-1301 in IgA nephropathy (IgAN).
  • IgAN, also known as Berger's disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues.
  • As of the May 6 data cutoff, BION-1301 has been well-tolerated, with no serious adverse events or treatment discontinuations due to adverse events.
  • BION-1301 demonstrated mean IgA and IgM reductions at a steady state of greater than 65%, while mean IgG levels were reduced by only 30-40%.
  • IgG level fell below the study-defined threshold in one patient, necessitating protocol-mandated withholding of BION-1301. There have been no infections reported in this patient.
  • BION-1301 demonstrated a 48.8% geometric mean reduction in 24-hour urine protein creatinine ratio (UPCR) in all eight patients at six months of treatment, a 70.9% in six patients at one year of treatment, and a 69.1% in two patients at 1.5 years of treatment.
  • Cohort 2 in Part 3 is currently enrolling additional patients. Initial data from Cohort 2 is expected in 2H 2022. 
  • Chinook plans to initiate a phase 3 trial of BION-1301 for patients with IgAN in 2023.
  • Price Action: KDNY shares are up 10.30% at $13.88 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!